Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS (aHUS)
An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)
Sponsor: Alexion Pharmaceuticals, Inc.
Listed as NCT00844844, this PHASE2 trial focuses on Atypical Hemolytic Uremic Syndrome and remains completed. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Dec 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2023 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alexion Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Atlanta, United States , Bordeaux, France , Essen, Germany , Fort Wayne, United States , Grapevine, United States , Houston, United States , Innsbruck, Austria , Lyon, France , Nantes, France and 6 more locations